

## NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

### Non-Hodgkins Lymphoma (NHL)

#### First Guideline Development Group (GDG) meeting

4<sup>th</sup> & 5<sup>th</sup> March 2014

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

#### GROUP MEMBERSHIP & ACTION LIST

GDG Members	
David Linch (DL)	Christopher McNamara (CM)
Andrew Jack (AJ)	Bhuey Sharma (BS)
Peter Hoskin (PH)	Ian Chau (IC)
Kim Linton (KL)	Jennifer Wimperis (JW)
Graham Collins (GC)	Karl Peggs (KP)
Jacqueline Green (JG)	Gillian Howard-Jones (GHJ)
Katharine Robinson (KR)	Morag Day (MD)
Tessa Somerville (TS)	
NCC-C staff	
Dr John Graham (JG)	Matthew Prettyjohns (MP)
Dr Nathan Bromham (NB)	Sabine Berendse (SB)
Dr Andrew Champion (AC)	Deborah Fitzsimmons (DF)
Laura Bunting (LB)	Lianne Gwillim (LG)
Coral McCarthy (CMc)	
NICE staff	
Katie Perryman Ford (KPF) ( <i>Day 2 only</i> )	Erin Whittingham (EW) ( <i>Day 1 only</i> ) left at 15.30

#### REPORTS OF DISCUSSIONS AT THE MEETING

##### 1. Introductions

DL welcomed everyone to the 1<sup>st</sup> meeting of the Non-Hodgkin's Lymphoma GDG.

Apologies for absence were received from Katie Perryman Ford (NICE) can only attend day 2.

##### 2. Declarations of Interest

- DL declared that he received honoraria from Roche for attending advisory boards and giving lectures at sponsored meetings covering the treatment of Lymphoma and the development of monoclonal antibody treatments.
- DL declared that his Department receives funding from Chugai for of PHD studentships. Is co-supervisor.
- DL declared that he received honoraria from Chugai for attending advisory boards and giving lectures at sponsored meetings covering the treatments of neutropenia and therapy induced neutropenia and rheumatoid arthritis. This interest was categorised as personal pecuniary

interest, non-specific meaning that DL can declare and participate in discussions on all topics as guideline is not covering treatments of neutropenia and therapy induced neutropenia and rheumatoid arthritis.

- DL declared that he is Medical Advisor to Cellectis. This interest was categorised as personal pecuniary interest, non-specific meaning that DL can declare and participate in discussions on all topics. Email received from JG conforming from Andrew Dillon that DL can continue as a medical advisor to Cellectis whilst chairing the guideline.
- DL declared that he is Chair of Safety Committee for Cell Medica. Safety oversight of two early phase clinical trials of anti-CMV specific T-cell lymphocytes. This interest was categorised as personal non-pecuniary interest meaning that DL can declare and participate in discussions on all topics as guideline is not covering anti-CMV specific T-cell lymphocytes.
- DL declared that he is a member of the safety/oversight committee for Cellgene. Safety trial of lenalidomide in relapsed lymphoma. . This interest was categorised as personal non-pecuniary interest meaning that DL can Declare and participate in discussions on all topics as lenalidomide is being investigated by TA's and therefore will not be investigated by the guideline. *Note: 28.02.14 David Linch has resigned from committee.*
- DL declared that he is president of the Lymphoma Association. This interest was categorised as personal non-pecuniary interest meaning that DL can declare and participate in discussions on all topics as this interest is not specific to the content of the guideline.
- DL declared that his department receives funding from Astra Zeneca for PHD studentships. No direct involvement. This interest was categorised as non-personal pecuniary interest, non-specific meaning that DL can declare and participate in discussions on all topics as does not have supervisory responsibility for PHD students.
- AJ declared that he received reimbursement of travelling and subsistence expenses from Roche for attending the American Society of Haematologists (ASH) meeting in December 2013. This interest was categorised as personal pecuniary interest, specific meaning that AJ can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- AJ declared that he is a member of a the trial management group for a Phase III randomised clinical trial comparing rituximab given every 14 days with CHOP given every 21 days (R-CHOP 14 vs21) for patients with newly diagnosed diffuse large B Cell non Hodgkins Lymphoma. Funded by Cancer Research UK and Chugai Pharma Europe Ltd.. This interest was categorised as non-personal pecuniary interest, specific meaning that AJ can declare and participate in discussions on all topics as no supervisory responsibility on trials
- AJ declared that he is principal investigator for a randomised evaluation of molecular targeted therapy with bortezomib in diffuse large B-cell lymphoma (REMoDL-B). Funded by Janssen-Cilag. This interest was categorised as non-personal pecuniary interest, specific meaning that AJ can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- AJ declared that he is principal investigator for biomarker development and monoclonal antibodies for the treatment of lymphoma. Funded by Genentech Ltd. This interest was categorised as non-personal pecuniary interest, specific meaning that AJ can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- AJ declared that he is principal investigator on a trial to compare remission rates of low grade non Hodgkin's lymphoma with GA101 vrs rituximab. Funded by Experimental Cancer Medicine (ECMC), Genentech Ltd, NCRN and Roche. This interest was categorised as non-personal pecuniary interest, specific meaning that AJ can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- AJ declared that he is principal investigator on the stratification of treatment by molecular and genetic sub-typing for diffuse large B-cell lymphoma. Funded by Leukaemia and lymphoma research. This interest was categorised as non-personal pecuniary interest, specific meaning that AJ can declare and participate in discussions on all topics as no supervisory responsibility on trials.

- AJ declared that he represents the NCRI on the Lunenburg lymphoma biomarker consortium, the European and North American initiative for the development of biomarkers in clinical trials. This interest was categorised as personal non-pecuniary. Chair person's action that AJ can declare and participate in discussions on all topics as the interest is not specific to the content of the guideline.
- AJ declared that his Host Trust is contracted to provide diagnostic services for the GALLIUM trial to Roche. Responsible for supervising staff and ensuring the work is carried out to the required quality in line with the contract. This interest was categorised as non-personal pecuniary interest, specific meaning that AJ can declare and participate in discussions on all topics as individual has no responsibility for the contract and does not provide any advice or opinion to Roche.
- AJ declared that he has supervisory responsibility for a collaborative research project to identify targets for therapeutic antibody development. Funded by Genetech. This interest was categorised as non-personal pecuniary interest, non-specific meaning that AJ can declare and participate in discussions on all topics as therapeutic antibody development is not the focus of the guideline.
- JG declared that she explains the MDSBio Study of Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesis to haematology patients with abnormal blood count. This interest was categorised as non-personal pecuniary interest, non-specific meaning that JG can declare and participate in discussions on all topics as myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesis is not the focus of the guideline.
- JG declared that she is a member of the London Cancer Alliance, haematology pathway lead nurse group. This interest was categorised as personal non-pecuniary interest. Chair person's action that JG can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared he received reimbursement of travelling expenses and conference registration fee for attending the European Society for Radiation and Oncology (ESTRO) in December 2013. This interest was categorised as personal pecuniary interest, non-specific meaning that PH can declare and participate in discussions on all topics as expenses were not beyond reasonable amounts.
- PH declared he is a chief investigator for a trial investigating brachytherapy +/- external beam radiotherapy, which received funding from Dept of Health and CRUK. Continues to follow those patients up and publish data from the study. This interest was categorised as non-personal pecuniary interest, non-specific meaning that PH can declare and participate in discussions on all topics as brachytherapy +/- external beam radiotherapy is not being covered by the guideline.
- PH declared that he holds a research grant from Varian which pays the salary for a data manager working on HDR boost, for Brachytherapy in prostate cancer. This interest was categorised as non personal pecuniary interest, non-specific meaning that PH declare and participate in discussions on all topics as brachytherapy and prostate cancer is not being covered by the guideline.
- PH declared that his department has been reimbursed for studies on abiraterone by Cougar. This interest was categorised as non-personal pecuniary interest, non-specific meaning PH can declare and participate in discussions on all topics as abiraterone for prostate cancer is not being covered by the guideline.
- PH declared that his department has been reimbursed for studies on alfaradin by Astellas. This interest was categorised as non-personal pecuniary interest, non-specific meaning PH can declare and participate in discussions on all topics as alfaradin for prostate cancer is not being covered by the guideline.
- PH declared that his department has been reimbursed for studies on MDV 3100 by Medivation. This interest was categorised as non-personal pecuniary interest, non-specific

meaning PH can declare and participate in discussions on all topics as MDV 3100 for prostate cancer is not being covered by the guideline.

- PH declared that his department has been reimbursed for studies on Denosumab for prostate cancer. Funded by Amgen. This interest was categorised as non-personal pecuniary interest, non-specific meaning PH can declare and participate in discussions on all topics as Denosumab for prostate cancer is not being covered by the guideline.
- PH declared that he is a trustee for funding research within the unit/department. Funded by Donations/Legacies. No Non-Hodgkins lymphoma research has been funded in the last 12 months. This interest was categorised as personal non-pecuniary interest meaning PH can declare and participate in discussions on all topics as no Non-Hodgkins lymphoma research has been funded in the last 12 months.
- PH declared he chairs Steering Group for the National Cancer Intelligence Network (NCIN). This interest was categorised as personal non-pecuniary interest meaning that PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared he is a member of the committee for Medical Aspects of Radiation Exposure (COMARE). This interest was categorised as personal non-pecuniary interests meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared he is a member of the faculty board of the Royal College of Radiologists. This interest was categorised as personal non-pecuniary interest meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared his a member of the specialist training committee for the Royal College of Radiologists. This interest was categorised as personal non-pecuniary interest meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared his is a member of the specialist training advisory committee (STAC) for the Royal College of Radiologists. This interest was categorised as personal non-pecuniary interest meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared that he is an editorial board member for the Journal of Clinical Oncology. This interest was categorised as personal non-pecuniary interest meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared that he is an editorial board member for the Journal of Bone Oncology. This interest was categorised as personal non-pecuniary interests meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared that he is an editorial board member for the Journal of Contemporary Brachytherapy. This interest was categorised as personal non-pecuniary interest meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared that is a member of the East of England senate. This interest was categorised as personal non-pecuniary interest meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared that he is a member on the NICE standing committee for rapid updates. This interest was categorised as personal non-pecuniary interest meaning PH can declare and participate in discussions on all topics as not specific to the content of the guideline.
- PH declared that his department receives grants from Astellas for trials in prostate cancer. This interest was categorised as non-personal pecuniary interest, non- specific meaning PH can declare and participate in discussions on all topics as prostate cancer is not being covered by the guideline.
- PH declared that his department receives grants from Bayer for trials in prostate cancer. This interest was categorised as non-personal pecuniary interest, non- specific meaning PH can declare and participate in discussions on all topics as prostate cancer is not being covered by the guideline.

- PH declared that his department receives grants from Millennium for trials in prostate cancer. This interest was categorised as non-personal pecuniary interest, non-specific meaning PH can declare and participate in discussions on all topics as prostate cancer is not being covered by the guideline.
- PH declared that his department receives grants from Varian for trials in prostate cancer. This interest was categorised as non-personal pecuniary interest, non-specific meaning PH can declare and participate in discussions on all topics as prostate cancer is not being covered by the guideline.
- IC declared that he attended an advisory board for factors to consider for patients with metastatic colorectal cancer. Hosted by Sanofi Oncology no payment was received. This interest was categorised as personal non-pecuniary interest meaning IC can declare and participate in discussions on all topics as GI cancer is not being covered by the guideline.
- IC declared that he attended an advisory board for GI cancers. Hosted by Eli Lilly, no payment was received. This interest was categorised as personal non-pecuniary interest meaning IC can declare and participate in discussions on all topics as GI cancer is not being covered by the guideline.
- IC declared that he attended an advisory board for Anti-CD30 antibody drug conjugate therapy in Hodgkins and CD30+ and oral discussion on JSPAC01 and SOFT studies. Hosted by Taiho, no payment was received. This interest was categorised as personal non-pecuniary interest meaning IC can declare and participate in discussions on all topics as Hodgkins lymphoma is not being covered by the guideline.
- IC declared that he attended an advisory board for GI cancers. Hosted by Gilead, no payment was received. This interest was categorised as personal non-pecuniary interest meaning IC can declare and participate in discussions on all topics as GI cancer is not being covered by the guideline.
- IC declared that he received reimbursement of travelling expenses and subsistence from Sanofi Oncology for attending the World Congress on GI cancers. This interest was categorised as personal pecuniary interest, specific meaning IC can declare and participate in discussions on all topics as expenses were not beyond reasonable amounts.
- IC declared that he received reimbursement of travelling expenses and subsistence from Sanofi Oncology for attending the European Society of Medical Oncology (ESMO) meeting. This interest was categorised as personal pecuniary interest, non-specific meaning IC can declare and participate in discussions on all topics as expenses were not beyond reasonable amounts.
- IC declared that he is chief investigator and involved in developing the trial protocol for the PERU trial. A multi-centre randomised phase II clinical study of UFT, radiotherapy with or without cetuximab following induction gemcitabine plus capecitabine in patients with locally advanced pancreatic cancer. Funded by Merck Serono. This interest was categorised as non-personal pecuniary interest, non-specific meaning IC can declare and participate in discussions on all topics as locally advanced pancreatic cancer is not being covered by the guideline.
- IC declared he is chief investigator and involved in developing the trial protocol for the CALIVER trial. A multi-centre randomised phase II clinical study of aflibercept plus chemotherapy in patients with colorectal liver-only metastases deemed to be inoperable or unsuitable for upfront liver resection. Funded by Sanofi Oncology. . This interest was categorised as non-personal pecuniary interest, non-specific meaning IC can declare and participate in discussions on all topics as colorectal liver-only metastases are not being covered by the guideline.
- IC declared he is Co-investigator on a multicentre randomised phase II study of CHEMO-T, Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment of T-cell lymphoma. Funded by Leukaemia and Lymphoma Research. This interest was categorised as non-personal pecuniary interest, specific meaning IC can declare and participate in discussions on all topics as no supervisory responsibility on trials.

- IC declared he is a member of the UK primary CNS lymphoma group. This interest was categorised as personal non-pecuniary interest meaning IC can declare and participate in discussions on all topics as not specific to the content of the guideline.
- JW declared that she received reimbursement of travelling expenses and subsistence from Boehringer Ingelheim for attending the European Haematology Association meeting. This interest was categorised as personal pecuniary interest, specific meaning JW can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- JW declared that she is Principal investigator on a multicentre randomised phase II study on CHEMO-T, Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment of T-cell lymphoma. Funded by NIHR. This interest was categorised as non-personal pecuniary interest, specific meaning JW can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- JW declared that she is Principal investigator on the bright light survey, a quality assessment of all cancers of teenagers and young adults. Funded by NIHR. This interest was categorised as non-personal pecuniary interest, non-specific meaning JW can declare and participate in discussions on all topics as quality assessment of all cancers of teenagers and young adults is not being covered by the guideline.
- JW declared that she is Principal investigator and local administrator on a multicentre randomised phase II study on RATHL, to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin's lymphoma. This interest was categorised as non-personal pecuniary interest, non-specific meaning JW can declare and participate in discussions on all topics as Hodgkin's lymphoma is not being covered by the guideline.
- JW declared that she is gatekeeper for three endowment funds used for research projects within department. If requests are above £1000 then the request is referred to the trust committee. No non-Hodgkins lymphoma related research has been funded in the last 12 months. This interest was categorised as personal non-pecuniary interest meaning JW can declare and participate in discussions on all topics as no non-Hodgkins lymphoma related research has been funded in the last 12 months.
- JW declared that she is Trustee for the Big C cancer charity. Helps direct the activities of the charity, signs off allocation of grants and general governance. No non-Hodgkins lymphoma related research has been funded in the last 12 months. This interest was categorised as personal non-pecuniary interest meaning JW can declare and participate in discussions on all topics as no non-Hodgkins lymphoma related research has been funded in the last 12 months.
- JW declared that she is Chair of the BCSH guideline committee. This interest was categorised as personal non-pecuniary interest meaning JW can declare and participate in discussions on all topics.
- BS declared that he received honoraria from Roche for attending and giving a lecture on breast cancer imaging at a breast cancer meeting in London. This interest was categorised as personal pecuniary non-specific interest meaning that BS can declare and participate in discussions on all topics as breast cancer is not being covered by the guideline.
- BS declared that he is co-investigator on a multicentre randomised phase II study on CHEMO-T, Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment of T-cell lymphoma. Funded by Royal Marsden NHS Foundation trust. This interest was categorised as non-personal pecuniary specific meaning that BS can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- BS declared that he is Co-investigator on a multicentre randomised phase II study on LEGEND comparing Lenalidonmide plus rituximab, gemcitabine, methylprednisolone and cisplatin (RG-EMP) in second line treatment of diffuse large B-cell lymphoma. Funded by Celgene Europe Ltd. This interest was categorised as non-personal pecuniary interest,

specific meaning that BS can declare and participate in discussions on all topics as no supervisory responsibility on trials.

- KP declared that he received honoraria for attending the European Millennium Takeda Advisory Board on the role of transplantation in Hodgkin Lymphoma. This interest was categorised as non-personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as Hodgkin lymphoma is not being covered by the guideline.
- KP declared that he received honoraria for attending the MSD global advisory board to discuss the trial design for their phase II study of letermovir (an anti-CMV drug). This interest was categorised as personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as cytomegalovirus infections are not being covered by the guideline.
- KP declared that he received honoraria for attending the MSD advisory board that covered the role of oral antifungal in bone marrow transplant patients and acute myeloid leukaemia. This interest was categorised as personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as bone marrow transplant patients and acute myeloid leukaemia is not being covered by the guideline.
- KP declared that he received travel and subsistence for acting as an advisor to Selectis who make genetically modified cells for treating infection. This interest was categorised as personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- KP declared that he received reimbursement of travelling expenses and subsistence for attending the international Society for Hodgkin's lymphoma debate on the role of transplantation in patients with Hodgkin's lymphoma. This interest was categorised as personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- KP declared that he received reimbursement of travelling expenses and subsistence for attending the Controversies in stem cell transplantation debate on the role of allogeneic transplantation in patients with Hodgkin's lymphoma. This interest was categorised as personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- KP declared that he received reimbursement of travelling expenses and subsistence for attending the Cellular therapy meeting where cell therapy for oral infections was discussed. This interest was categorised as personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- KP declared that he is principal investigator on the ProT4, NCRN phase II study of prophylactic CD8-depleted DLI following T-cell depleted reduced intensity allogeneic transplantation. Funded by Leukaemia and Lymphoma research. This interest was categorised as non-personal pecuniary interest, specific meaning that KP can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- KP declared that he is principal investigator on the LenaRIC, NCRB phase II study of allogeneic transplantation with post transplant lenalidomide and donor-lymphocytes in multiple myeloma. Funded by CTAAC. This interest was categorised as non-personal pecuniary interest, specific meaning that KP can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- KP declared that he is Chief investigator and involved in developing the trial protocol for the PAIReD, a national joint NCRN/BSBMT phase II study of reduced intensity allogeneic transplantation in primary resistant and relapsed refractory patients with Hodgkin's lymphoma. Funded by CRUK, Chugai, Pharma UK Ltd, ECMC, NCRN and UCL. This interest was categorised as non-personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as Hodgkin lymphoma is not being covered by the guideline.

- KP declared that he is Chief investigator and involved in developing the trial protocol for the CMV-ACE/ASPECT, a multi centre phase II study of pre-emptive CMV specific T –cell lymphocytes in related donor allogeneic transplantation (Relating to the use of anti-viral immune cells to treat viral infections). Funded by Leukaemia and Lymphoma Research Cell Medica Ltd. This interest was categorised as non-personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as anti-viral immune cells to treat viral infections is not being covered by the guideline.
- KP declared that he is Chief investigator and involved in developing the trial protocol for the CMV IMPACT a multi centre randomised confirmatory national study of prophylactic CMV-specific T-cell lymphocytes depleted sibling allogeneic transplantation. (Relating to the use of anti-viral immune cells to treat viral infections). Funded by Cell Medica Ltd, ECMC, and the Wellcome trust. This interest was categorised as non-personal pecuniary interest, non-specific meaning that KP can declare and participate in discussions on all topics as anti-viral immune cells to treat viral infections is not being covered by the guideline.
- KP declared that he is a member of the NCRI lymphoma clinical studies group. This interest was categorised as personal non-pecuniary interest meaning that KP can declare and participate in discussions on all topics as not specific to the content of the guideline.
- GC declared that he received honoraria from Takeda for attending an advisory board on Brentuximab in the treatment of Hodgkin's lymphoma and anaplastic large T-Cell lymphoma. This interest was categorised as personal pecuniary interest, specific meaning GC must declare and withdraw from discussion on any topic on Brentuximab until October 2014.
- GC declared that he received honoraria from Mundipharma for attending a specialist nurses educational forum to present to lymphoma nurses indolent non-Hodgkin's lymphoma, covering first and second line chemotherapy and antibody options. This interest was categorised as personal pecuniary interest, specific meaning GC must declare and withdraw from discussion on any topic covering the first and second line treatment of indolent lymphoma until October 2014.
- GC declared that he received honoraria from Takeda for attending the American Society of Haematologists meeting and giving a presentation on Brentuximab in ALCL and Hodgkin's. This interest was categorised as personal pecuniary interest, specific meaning GC must declare and withdraw from discussion on any topic on Brentuximab until December 2014.
- GC declared that he received honoraria from Roche for attending a local nurse specialist group and giving a presentation on the updates in lymphoma, covering Ibrutinib and other targeted therapies. This interest was categorised as personal pecuniary interest, specific meaning GC must declare and withdraw from discussion on any topic where ibrutinib is an intervention until October 2014.
- GC declared that he received reimbursement of travelling expenses, subsistence and conference registration from Roche for attending the American Society of Haematologists meeting. This interest was categorised as personal pecuniary interest, specific meaning that GC can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- GC declared that he received reimbursement of travelling expenses and subsistence from Takeda for attending the International lymphoma meeting in Lugano. This interest was categorised as personal pecuniary interest, specific meaning that GC can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- GC declared that he is Principal investigator on the GALLIUM trial on rituximab versus GA101 in combination with chemotherapy in first-line follicular and marginal zone lymphoma. Funded by NCR, Roche, and the German low study group. This interest was categorised as non-personal pecuniary interest, specific meaning that GC can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- GC declared that he is principal investigator on the REMoDL\_B: R-Chop versus R-Chop+ bortezomib in first line treatment of diffuse large B-cell lymphoma. Funded by Janssen-Cilag. This interest was categorised as non-personal pecuniary interest, specific meaning that GC



can declare and participate in discussions on all topics as no supervisory responsibility on trials.

- GC declared that he is principal investigator on the Mabcute: 2 year rituximab maintenance versus ongoing until progression, in relapsed indolent non-Hodgkin's lymphoma. Funded by Roche. This interest was categorised as non-personal pecuniary interest, specific meaning that GC can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- GC declared that he is principal investigator on the Chemo T-CHOP versus GEM-P for first line treatment of peripheral T-cell lymphoma. Funded by NIHR. This interest was categorised as non-personal pecuniary interest, specific meaning that GC can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- GC declared that he is principal investigator on the AZD1152, a phase IIa trial on an aurora kinase B inhibitor in relapsed/refractory diffuse large B-cell lymphoma. Funded by Oxford University Hospitals NHS trust, Christie Hospital NHS foundation trust, University of Manchester Early Phase Cancer Research Hub, Oxford. This interest was categorised as non-personal pecuniary interest, specific meaning that GC can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- GC declared that he is Principal investigator on the GS-US-313-0125, phase III trial of rituximab + bendamustine with either idelalisib or placebo in relapsed/refractory indolent non-Hodgkin's lymphoma. Funded by Gilead. This interest was categorised as non-personal pecuniary interest, specific meaning that GC can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- GC declared that he is Chief investigator and involved in developing the trial protocol for the ECHALON-1 study, an international randomised trial of ABVD versus AVD + brentuximab vedotin in the first line treatment of advanced classic Hodgkin lymphoma Funded by Takeda. This interest was categorised as non-personal pecuniary interest, non-specific meaning that GC can declare and participate in discussions on all topics as Hodgkins lymphoma is not being investigated by the guideline.
- GC declared that he is chief investigator and involved in developing the trial protocol for the RomiCar trial, phase I/II trial investigating a novel drug combination in relapsed/refractory peripheral T-cell lymphoma with assessment of HR23B as predictive biomarker of response. This has been accepted onto the LLR Trials Acceleration Programme portfolio and is due to open Q4 2013. Funded by Leukaemia and Lymphoma Research, Onyx Therapeutics. This interest was categorised as non-personal pecuniary interest, specific meaning that GC must declare and withdraw from discussion on any topic on novel drug combinations in relapsed/refractory peripheral T-cell lymphoma.
- GC declared that is chief investigator and involved in developing the trial protocol for the PimTor phase I/II trial of a PIM inhibitor (AZD1208) and mTOR inhibitor (AZD2014) as single agents in combination, in relapsed/refractory B-cell non-Hodgkin's lymphoma. This is currently being prepared for funding submission to Astra Zeneca. This interest was categorised as non-personal pecuniary interest, specific meaning that GC must declare and withdraw from discussion on any topic on PIM inhibitor (AZD1208) and mTOR inhibitor (AZD2014) in relapsed/refractory B-cell non-Hodgkin's lymphoma.
- GC declared he is a member of the NCRI study group. This interest was categorised as personal non-pecuniary interest meaning that GC can declare and participate in discussions on all topics as not specific to the content of the guideline.
- GC declared he is a member of the lymphoma association. This interest was categorised as personal non-pecuniary interest meaning that GC can declare and participate in discussions on all topics as not specific to the content of the guideline.
- KL declared that she received honoraria for attending an advisory board on the role of pixantrone in the treatment of relapsed/refractory B-cell non-Hodgkins lymphoma. Payment was received from Cell therapeutics life sciences. This interest was categorised as personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all

topics as Pixantrone is being investigated by TA's and therefore will not be investigated by the guideline.

- KL declared that she received honoraria for attending an advisory board on Brentuximab vedotin in T-cell lymphoma and Hodgkin's disease. This interest was categorised as personal pecuniary interest, specific meaning that KL must declare and withdraw from discussion on any topic on Brentuximab vedotin until October 2014.
- KL declared that she received honoraria, travel and subsistence expenses from Pfizer for attending conference and being on panel discussing engaging with the NHS. This interest was categorised as personal pecuniary interest, non-specific meaning that KL can declare and participate in discussion on all topics as engaging with the NHS is not being investigated by the guideline.
- KL declared that she received reimbursement of travelling expenses and conference fee for attending the International malignant lymphoma meeting in June 2013. This interest was categorised as personal pecuniary interest, non-specific meaning that KL can declare and participate in discussions on all topics as expenses not beyond a reasonable amount.
- KL declared that she is principal investigator and involved in developing the trial protocol on the development of a molecular test for Diffuse large B-cell lymphoma molecular sub-type. Funded by Almac diagnostics, Affymetrix and MRC confidence in concept funding. This interest was categorised as non-personal pecuniary interest, specific meaning that KL must declare and withdraw from discussion on developing molecular tests for Diffuse large B-cell lymphoma.
- KL declared that she is Local Principal investigator on the CAL 101-09; Calistoga Phase II study investigating the efficacy and safety of PI3K delta inhibitor (CAL101) in patients with indolent B-cell non-Hodgkins lymphoma refractory to rituximab and alkylating agents. Funded by Gilead Science. This interest was categorised as non-personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- KL declared that she is local principal investigator on the DLC001; Phase II/III study comparing lenalidomide with conventional single agent chemotherapy in patients with relapsed diffuse large b-cell lymphoma. Funded by Celgene. This interest was categorised as non-personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all topics as lenalidomide is being investigated by TA's and therefore will not be investigated by the guideline.
- KL declared that she is local principal investigator on the IELSG-32; investigator-led randomised phase 3 trial on primary chemotherapy with high dose methotrexate and high dose cytarabine with or without thiotepa, and with or without rituximab, followed by whole brain irradiation vs. high dose chemotherapy supported by autologous stem cell transplantation for immunocompetent patients with newly diagnosed primary CNS lymphoma. This interest was categorised as non-personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all topics as no supervisory responsibility on trials and newly diagnosed primary CNS lymphoma is not being investigated by the guideline.
- KL declared that she is principal investigator on the Bayer 16349; Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's. Funded by Bayer. This interest was categorised as non-personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- KL declared that she is local principal investigator on the ARROVEN, Takeda sponsored post authorisation safety assessment of Brentuximab Vedotin treatment in relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. Funded by Takeda. This interest was categorised as non-personal pecuniary interest, non-specific meaning that KL can declare and participate in discussions on all topics as no supervisory responsibility on trials and Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma are excluded from the scope of the guideline.

- KL declared that she is local principal investigator on the Gilead 0125 trial, a randomised phase III trial investigating the addition of Idelalisib to the Rituximab -Bendamustine combination in relapsed/refractory indolent B cell NHL. This interest was categorised as non-personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- KL declared that she is principal investigator on the ReBel trial; International phase 1/2 study investigating the combination of rituximab and lenalidomide +/- bendamustine in patients with relapsed follicular lymphoma, expected to start recruiting in Q1 2014. Funded by Hovon, GLSG & Celgene. This interest was categorised as non-personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- KL declared that she is co-investigator on the INCA trial, a multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IORCVP) versus Gemcitabine plus Rituximab and CVP (GemRCVP) for the first line treatment of patients with diffuse large B cell lymphoma who are not suitable for anthracycline containing chemotherapy. Funded by Pfizer. This interest was categorised as non-personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- KL declared that she is co-investigator on the RomiCar study. A phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma. Funded by Leukaemia and Lymphoma Research, and Onyx Therapeutics. This interest was categorised as non-personal pecuniary interest, specific meaning that KL can declare and participate in discussions on all topics as no supervisory responsibility on trials.
- KL declared that she is co investigator on the BREVITY study. A phase II study of brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy. Funded by Millennium. This interest was categorised as non-personal pecuniary interest, non-specific meaning that KL can declare and participate in discussions on all topics as relapsed Hodgkin Lymphoma is not being investigated by the guideline.
- KL declared that she is co- investigator on the Relapsed primary CNS lymphoma trial. Funded by LLR TAP. This interest was categorised as personal non-pecuniary interest, non-specific meaning that KL can declare and participate in discussions on all topics as newly diagnosed primary CNS lymphoma is not being investigated by the guideline.
- KL declared that she is chair of the Lymphoma Translational Research Group, Manchester. This interest was categorised as personal non-pecuniary interest meaning that KL can declare and participate in discussions on all topics as not specific to the content of the guideline.
- KL declared that she is a Lymphoma DG representative on MCRC Biobank Management Board. This interest was categorised as personal non-pecuniary interest meaning that KL can declare and participate in discussions on all topics as not specific to the content of the guideline.
- KL declared that she is Advisor for the Clinical Outcomes Group (Lymphoma DG). This interest was categorised as personal non-pecuniary interest meaning that KL can declare and participate in discussions on all topics as not specific to the content of the guideline.
- KL declared that she is a member of BCSH writing group – DLBCL guidelines. This interest was categorised as personal non-pecuniary interest meaning that KL can declare and participate in discussions on all topics as not specific to the content of the guideline.
- KL declared that she is a member of NCRN low grade lymphoma sub group and biological studies sub group. This interest was categorised as personal non-pecuniary interest meaning that KL can declare and participate in discussions on all topics as not specific to the content of the guideline.
- GHJ declared that she received honoraria from Roche for presenting preparing for patient triggered follow-up at the CNS lymphoma forum. This interest was categorised as personal

pecuniary interest meaning that GHJ must declare and withdraw from discussion on any topic on patient triggered follow-up until November 2014.

The following interests were declared at the meeting:

- CM declared that he is the principle investigator for the GALLIUM trial on rituximab versus GA101 in combination with chemotherapy in first-line follicular and marginal zone lymphoma. Funded by NCR and Roche. Advised on setting up the laboratory diagnostics for patients participating in the trial, when the trial protocol was being determined. This interest was categorised as non-personal pecuniary specific meaning that CM can declare and participate in discussions on all topics as CM only provided advice on laboratory diagnostics components of the trial protocol.
- CM declared that he is the local principle investigator for the PACIFICO trial (Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP (rituximab, cyclophosphamide, vincristine and prednisone) versus R-FC (rituximab, fludarabine and cyclophosphamide). Funded by CTAAC. This interest was categorised as non-personal pecuniary specific, meaning that CM can declare and participate in discussions on all topics as CM has no supervisory responsibility for the trial.
- CM declared that he is the local principle investigator for the REMoDLB trial (A randomised evaluation to see whether adding bortezomib to standard combination chemotherapy and rituximab (RCHOP) can improve progression free survival in diffuse large B-cell lymphoma with Bortezomib). Funded by Janssen Cilag Ltd. This interest was categorised as non-personal pecuniary specific, meaning that CM can declare and participate in discussions on all topics as CM has no supervisory responsibility for the trial
- CM declared that he is the local principle investigator for the RATHL trial (a multicentre randomised phase II study to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin's lymphoma). Funded by CRUK. This interest was categorised as non-personal pecuniary non-specific, meaning that CM can declare and participate in discussions on all topics as Hodgkin's lymphoma is not being covered by the guideline.
- CM declare that he is the local principle investigator for the RAPID trial (A randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease). Funded by Leukaemia and Lymphoma Research. This interest was categorised as non-personal pecuniary non-specific, meaning that CM can declare and participate in discussions on all topics as Hodgkin's lymphoma is not being covered by the guideline.
- CM declared that he is a medical advisor to the Lymphoma Association. This interest was categorised as personal non-pecuniary meaning that CM can declare and participate in discussions on all topics as this interest is not specific to the content of the guideline.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

### 3. Discussions

The GDG were given presentations on:

- Introduction to NICE & NCC-C
- An overview of the guideline development process
- Time table for guideline development
- Patient & carer involvement in guideline development
- Guideline methodology development
- Health Economics in NICE guidelines

The GDG discussed the guideline scope and the topics that will be investigated. The group then drafted and agreed a PICO question for topics B, C, D, E, F, H, I, J, L, M, N, O, P & Q

The GDG discussed topics which were potential priorities for economic investigation.

**4. Close of meeting**

DL thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Monday 7<sup>th</sup> April 2014**, starting at 10.30, 51 Chenies Mews, Bloomsbury, London and closed the meeting.